Project Grant R43HL172410
Award Date
9/17/24
Completion Date
9/16/25
Dollars Obligated
$296K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This $550,000 Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of a non-invasive, multiplex blood test for the early detection of preeclampsia, a serious pregnancy complication. The project aims to advance the detection of vascular dysfunction, particularly preeclampsia, by optimizing a blood test that targets disease-inducing signaling proteins on the surface of...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development and testing of a novel wearable device to continuously and accurately measure blood loss for postpartum hemorrhage (PPH) prevention. The $639,165 award, spanning May 2025 to February 2030, supports research at Washington University to design a light-based sensor that can estimate cardiovascular parameters and...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $585,794 to Tele-Stethoscope Inc., a self-certified small disadvantaged business, to develop a novel mobile phone technology that can detect preeclampsia and hypertension. The key products to be delivered under this award include: Proof-of-concept demonstration that ordinary mobile phones can accurately reproduce a physician's diagnosis of preeclampsia....
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...
This $2,559,308 Project Grant was awarded on January 14, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a study examining the impact of severe pre-eclampsia on heart function in a racially diverse cohort of women during and after pregnancy. The study aims to characterize the cardiomyopathic genetic profile of participants and assess the functional impact of specific genetic...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Akna Health Inc. a $151,600 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to develop a point-of-care diagnostic solution for early identification of high-risk pregnancies. The research aims to validate the clinical relevance of cervical biomarkers as predictors of perinatal complications, such as fetal growth restriction, miscarriage, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $869,696 to Vanderbilt University Medical Center to investigate the relationship between preeclampsia during pregnancy and the development of heart failure with preserved ejection fraction (HFpEF) in women. The key objectives are to: 1) measure the relationship between post-partum subclinical left ventricular diastolic dysfunction and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $288,043 to Glycodots LLC to develop a rapid diagnostic test (EPX-RDT) that can detect eosinophil peroxidase (EPX) from nasal swab samples. The goal is to create a non-invasive, point-of-care tool to diagnose and manage asthma by measuring EPX, an important biomarker associated with...